Wyden says Medicaid may have "grossly" overpaid for EpiPens
September 02, 2016 at 16:55 PM EDT
Wyden contends Mylan may have misclassified the EpiPen as a generic device under the Medicaid program, thus reducing the rebates it pays.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|